Genetics, diagnosis and management of colorectal cancer (Review)
- Authors:
- Marina De Rosa
- Ugo Pace
- Daniela Rega
- Valeria Costabile
- Francesca Duraturo
- Paola Izzo
- Paolo Delrio
-
Affiliations: Department of Molecular Medicine and Medical Biotechnology, University of Naples ‘Federico II’, I-80131 Naples, Italy, Colorectal Surgical Oncology-Abdominal Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, ‘Fondazione Giovanni Pascale’ IRCCS, I-80131 Naples, Italy - Published online on: July 3, 2015 https://doi.org/10.3892/or.2015.4108
- Pages: 1087-1096
-
Copyright: © De Rosa et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
This article is mentioned in:
Abstract
|
Pancione M, Remo A and Colantuoni V: Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012:5093482012. View Article : Google Scholar | |
|
Ewing I, Hurley JJ, Josephides E and Millar A: The molecular genetics of colorectal cancer. Frontline Gastroenterol. 5:26–30. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Burt RW: Colon cancer screening. Gastroenterology. 119:837–853. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Jasperson KW, Tuohy TM, Neklason DW and Burt RW: Hereditary and familial colon cancer. Gastroenterology. 138:2044–2058. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Duraturo F, Liccardo R, Cavallo A, De Rosa M, Grosso M and Izzo P: Association of low-risk MSH3 and MSH2 variant alleles with Lynch syndrome: Probability of synergistic effects. Int J Cancer. 129:1643–1650. 2011. View Article : Google Scholar | |
|
Rustgi AK: The genetics of hereditary colon cancer (Review). Genes Dev. 21:2525–2538. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Peifer M: Developmental biology: colon construction. Nature. 420:274–275. 2772002. View Article : Google Scholar : PubMed/NCBI | |
|
Kosinski C, Li Vs, Chan AS, Zhang J, Ho C, Tsui WY, Chan TL, Mifflin RC, Powell DW, Yuen ST, et al: Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc Natl Acad Sci USA. 104:15418–15423. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Medema JP and Vermeulen L: Microenvironmental regulation of stem cells in intestinal homeostasis and cancer (Review). Nature. 474:318–326. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, et al: The CPG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 132:127–138. 2007. View Article : Google Scholar | |
|
Sideris M and Papagrigoriadis S: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer (Review). Anticancer Res. 34:2061–2068. 2014.PubMed/NCBI | |
|
Pino MS and Chung DC: The chromosomal instability pathway in colon cancer. Gastroenterology. 138:2059–2072. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Boland CR and Goel A: Microsatellite instability in colorectal cancer (Review). Gastroenterology. 138:2073–2087.e3. 2010. View Article : Google Scholar | |
|
Colussi D, Brandi G, Bazzoli F and Ricciardiello L: Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci. 14:16365–16385. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Markowitz SD and Bertagnolli MM: Molecular Origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Najdi R, Holcombe RF and Waterman ML: Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog. 10:52011. View Article : Google Scholar : PubMed/NCBI | |
|
MacDonald BT, Tamai K and He X: Wnt/β-catenin signaling: components, mechanisms and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Polakis P: Wnt signaling and cancer. Genes Dev. 14:1837–51. 2000.PubMed/NCBI | |
|
Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 1653:1–24. 2003.PubMed/NCBI | |
|
Dejana E: The role of wnt signaling in physiological and pathological angiogenesis. Circ Res. 107:943–952. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Planutis K, Planutiene M and Holcombe RF: A novel signaling pathway regulates colon cancer angiogenesis through Norrin. Sci Rep. 4:56302014. View Article : Google Scholar : PubMed/NCBI | |
|
Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Testa JR and Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Martini M, De Santis MC, Braccini I, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Porta C, Paglino C and Mosca A: Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee G, Goretsky T, Managlia E, Dirisina R, Singh AP, Brown JB, May R, Yang GY, Ragheb JW, Evers BM, et al: Phosphoinositide 3-kinase signaling mediates β-catenin activation in intestinal epithelial stem and progenitor cells in colitis. Gastroenterology. 139:869–881. 2010. View Article : Google Scholar | |
|
Simpson L and Parsons R: PTEN: life as a tumor suppressor. Exp Cell Res. 264:29–41. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Salmena L, Carracedo A and Pandolf PP: Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Manfredi M: Hereditary hamartomatous polyposis syndromes: understanding the disease risks as children reach adulthood. Gastroenterol Hepatol (NY). 6:185–196. 2010. | |
|
Eng C: PTEN: one gene, many syndromes. Hum Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Galatola M, Paparo I, Duraturo F, Turano M, Rossi GB, Izzo P and De Rosa M: Β catenin and cytokine pathway dysregulation in patients with manifestations of the 'PTEN hamartoma tumor syndrome'. BMC Med Genet. 13:282012. View Article : Google Scholar | |
|
Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, et al: Subtle variations in Pten dose determine cancer susceptibility. Nat Genet. 42:454–458. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Paparo I, Rossi GB, Delrio P, Rega D, Duraturo F, Liccardo R, Debellis M, Izzo P and De Rosa M: Differential expression of PTEN gene correlates with phenotypic heterogeneity in three cases of patients showing clinical manifestations of PTEN hamartoma tumour syndrome. Hered Cancer Clin Pract. 11:82013. View Article : Google Scholar : PubMed/NCBI | |
|
Malumbres M and Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hallberg B, Rayter SI and Downward J: Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem. 269:3913–3916. 1994.PubMed/NCBI | |
|
Liebmann C: Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal. 13:777–785. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et al: KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 158:171–184. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen F and Castranova V: Nuclear factor-kappaB, an unappreciated tumor suppressor. Cancer Res. 67:11093–11098. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Perkins ND: NF-κB: tumor promoter or suppressor? Trends Cell Biol. 14:64–69. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Du Q and Geller DA: Cross-regulation between Wnt and NF-κB signaling pathways. For Immunopathol. Dis Therap. 1:155–181. 2010. | |
|
Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer. 12:1–15. 2013. View Article : Google Scholar | |
|
Mccubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, et al: GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 5:2881–2911. 2014.PubMed/NCBI | |
|
Li H, Huang K, Liu X, Liu J, Lu X, Tao K, Wang G and Wang J: Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3β/NF-κb signaling pathway. Oxid Med Cell Longev. 2014:2418642014. View Article : Google Scholar | |
|
Mishra R: Glycogen synthase kinase 3β: can it be a target for oral cancer. Mol Cancer. 9:1442010. View Article : Google Scholar | |
|
Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB, Agrawal D, et al: EMT is the dominant program in human colon cancer. BMC Med Genomics. 4:92011. View Article : Google Scholar : PubMed/NCBI | |
|
De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J and García De Herreros A: The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Pei D, Zheng H and Li X1: Transitions between epithelial and mesenchymal states during cell fate conversions. Protein Cell. 5:580–591. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Giannelli G, Villa E and Lahn M: Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res. 74:1890–1894. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Costabile V, Duraturo F, Delrio P, Rega D, Pace U, Liccardo R, Rossi GB, Genesio R, Nitsch L, Izzo P, et al: Lithium chloride induces mesenchymal to epithelial reverting transition in primary colon cancer cell cultures. Int J Oncol. 46:1913–1923. 2015.PubMed/NCBI | |
|
Jasperson KW, Tuohy TM, Neklason DW and Burt RW: Hereditary and familial colon cancer. Gastroenterology. 138:2044–2058. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gallagher DJ, Smith JD, Offit K and stadler ZK: Diagnosing hereditary colorectal cancer. Clin Colorectal Cancer. 9:205–211. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lucci-Cordisco E, Risio M, Venesio T and Genuardi M: The growing complexity of the intestinal polyposis syndromes. Am J Med Genet A. 161A:2777–2787. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
De Rosa M, Duraturo F, Liccardo R and Izzo P: Hereditary gastrointestinal polyposis: diagnosis, genetic test and risk assessment. Open J Genet. 3:50–58. 2013. View Article : Google Scholar | |
|
Kolfschoten NE, Wouters MW, Gooiker GA, Eddes EH, Kievit J, Tollenaar RA and Marang-van de Mheen PJ: Dutch surgical colorectal audit group: nonelective colon cancer resections in elderly patients: results from the dutch surgical colorectal audit. Dig Surg. 29:412–419. 2012. View Article : Google Scholar | |
|
Smothers L, Hynan L, Fleming J, Turnage R, Simmang C and Anthony T: Emergency surgery for colon carcinoma. Dis Colon Rectum. 46:24–30. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kekelidze M, D'Errico L, Pansini M, Tyndall A and Hohmann J: Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol. 19:8502–8514. 2013. View Article : Google Scholar : | |
|
Leufkens AM, van den Bosch MA, van Leeuwen MS and Siersema PD: Diagnostic accuracy of computed tomography for colon cancer staging: a systematic review. Scand J Gastroenterol. 46:887–894. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J and Bouvier AM: Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 59:1383–1388. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Barret M, Boustiere C, Canard JM, Arpurt JP, Bernardini D, Bulois P, Chaussade S, Heresbach D, Joly I, Lapuelle J, et al: Société Française d'endoscopie Digestive: factors associated with adenoma detection rate and diagnosis of polyps and colorectal cancer during colonoscopy in France: results of a prospective, nationwide survey. PLoS One. 8:e689472013. View Article : Google Scholar | |
|
Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP and Butruk E: Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med. 362:1795–1803. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, et al: Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 366:687–696. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Graser A, Stieber P, Nagel D, Schäfer C, Horst D, Becker CR, Nikolaou K, Lottes A, Geisbüsch S, Kramer H, et al: Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut. 58:241–248. 2009. View Article : Google Scholar | |
|
Pickhardt PJ, Hassan C, Halligan S and Marmo R: Colorectal cancer: CT colonography and colonoscopy for detection - systematic review and meta-analysis. Radiology. 259:393–405. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pullens HJ, van Leeuwen MS, Laheij RJ, Vleggaar FP and Siersema PD: CT-colonography after incomplete colonoscopy: What is the diagnostic yield? Dis Colon Rectum. 56:593–599. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C, Edwards R, Yao G, Kay C, Burling D, Faiz O, et al: SIGGAR investigators: computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet. 381:1194–1202. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Edge SB and Compton CC: The American Joint Committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bipat S, Niekel MC, Comans EF, Nio CY, Bemelman WA, Verhoef C and Stoker J: Imaging modalities for the staging of patients with colorectal cancer. Neth J Med. 70:26–34. 2012.PubMed/NCBI | |
|
Floriani I, Torri V, Rulli E, Garavaglia D, Compagnoni A, Salvolini L and Giovagnoni A: Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging. 31:19–31. 2010. View Article : Google Scholar | |
|
Niekel MC, Bipat S and Stoker J: Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 257:674–684. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Dighe S, Blake H, Koh MD, Swift I, Arnaout A, Temple L, Barbachano Y and Brown G: Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. Br J Surg. 97:1407–1415. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Dighe S, Purkayastha S, Swift I, Tekkis PP, Darzi A, A'Hern R and Brown G: Diagnostic precision of CT in local staging of colon cancers: A meta-analysis. Clin Radiol. 65:708–719. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, Van de Velde CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 23:2479–2516. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I, Påhlman L, Quirke P, Valentini V and van de Velde C: Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol. 29:2142–2143. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Van de Velde CJ, Aristei C, Boelens PG, Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G, Coebergh JW, Cutsem EV, et al: European registration of cancer care: EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer. 49:2784–2790. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Torkzad MR, Påhlman L and Glimelius B: Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review. Insights Imaging. 1:245–267. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Poston GJ, Tait D, O'Connell S, Bennett A and Berendse S: Guideline development group: diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ. 343:d67512011. View Article : Google Scholar | |
|
Swartling T, Kälebo P, Derwinger K, Gustavsson B and Kurlberg G: Stage and size using magnetic resonance imaging and endosonography in neoadjuvantly-treated rectal cancer. World J Gastroenterol. 19:3263–3271. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hohenberger W, Weber K, Matzel K, Papadopoulos T and Merkel S: Standardized surgery for colonic cancer: complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Dis. 11:354–364; discussion 364–365. 2009. View Article : Google Scholar | |
|
Sehgal R and Coffey JC: Historical development of mesenteric anatomy provides a universally applicable anatomic paradigm for complete/total mesocolic excision. Gastroenterol Rep (Oxf). 2:245–250. 2014. View Article : Google Scholar | |
|
Søndenaa K, Quirke P, Hohenberger W, Sugihara K, Kobayashi H, Kessler H, Brown G, Tudyka V, D'Hoore A, Kennedy RH, et al: The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery: proceedings of a consensus conference. Int J Colorectal Dis. 29:419–428. 2014. View Article : Google Scholar | |
|
Siani LM and Pulica C: Stage I-IIIC right colonic cancer treated with complete mesocolic excision and central vascular ligation: quality of surgical specimen and long term oncologic outcome according to the plane of surgery. Minerva Chir. 69:199–208. 2014.PubMed/NCBI | |
|
Sagar J: Colorectal stents for the management of malignant colonic obstructions. Cochrane Database Syst Rev. 11:CD0073782011.Review. PubMed/NCBI | |
|
Fuccio L, Cennamo V and de Bellis M: Risk factors for stent-related adverse events in patients with obstructive colorectal cancer: are we missing something? Gastrointest Endosc. 80:742–743. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fuccio L, Correale L, Arezzo A, Repici A, Manes G, Trovato C, Mangiavillano B, Manno M, Cortelezzi CC, Dinelli M, et al: KRASTENT Study Group: influence of K-ras status and anti-tumour treatments on complications due to colorectal self-expandable metallic stents: a retrospective multicentre study. Dig Liver Dis. 46:561–567. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang TX and Chua TC: Single-incision laparoscopic colectomy versus conventional multiport laparoscopic colectomy: a meta-analysis of comparative studies. Int J Colorectal Dis. 28:89–101. 2013. View Article : Google Scholar | |
|
Mynster T, Hammer J and Wille-Jørgensen P: Preliminary results after single-port laparoscopic colonic surgery. Dan Med J. 59:A45512012. | |
|
Huscher CG, Mingoli A, Sgarzini G, Mereu A, Binda B, Brachini G and Trombetta S: Standard laparoscopic versus single-incision laparoscopic colectomy for cancer: early results of a randomized prospective study. Am J Surg. 204:115–120. 2012. View Article : Google Scholar | |
|
Wolthuis AM, Penninckx F, Fieuws S and D'Hoore A: Outcomes for case-matched single-port colectomy are comparable with conventional laparoscopic colectomy. Colorectal Dis. 14:634–641. 2012. View Article : Google Scholar | |
|
Ramos-Valadez DI, Ragupathi M, Nieto J, Patel CB, Miller S, Pickron TB and Haas EM: Single-incision versus conventional laparoscopic sigmoid colectomy: a case-matched series. Surg Endosc. 26:96–102. 2012. View Article : Google Scholar | |
|
Tyler JA, Fox JP, Desai MM, Perry WB and Glasgow SC: Outcomes and costs associated with robotic colectomy in the minimally invasive era. Dis Colon Rectum. 56:458–466. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Baek SK, Carmichael JC and Pigazzi A: Robotic surgery: colon and rectum. Cancer J. 19:140–146. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Glimelius B, Beets-Tan R, Blomqvist L, Brown G, Nagtegaal I, Påhlman L, Quirke P, Valentini V and van de Velde C: Mesorectal fascia instead of circumferential resection margin in preoperative staging of rectal cancer. J Clin Oncol. 29:2142–2143. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sgourakis G, Lanitis S, Gockel I, Kontovounisios C, Karaliotas C, Tsiftsi K, Tsiamis A and Karaliotas CC: Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg. 77:761–772. 2011.PubMed/NCBI | |
|
Guerrieri M, Gesuita R, Ghiselli R, Lezoche G, Budassi A and Baldarelli M: Treatment of rectal cancer by transanal endoscopic microsurgery: experience with 425 patients. World J Gastroenterol. 20:9556–9563. 2014.PubMed/NCBI | |
|
Matz J and Matz A: Use of a SILS port in transanal endoscopic microsurgery in the setting of a community hospital. J Laparoendosc Adv Surg Tech A. 22:93–96. 2012. View Article : Google Scholar | |
|
Atallah S, Albert M and Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc. 24:2200–2205. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM and Brown JM: MRC CLASICC trial group: short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 365:1718–1726. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jayne DG, Thorpe HC, Copeland J, Quirke P, Brown JM and Guillou PJ: Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg. 97:1638–1645. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kang SB, Park JW, Jeong SY, Nam BH, Choi HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, et al: Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol. 11:637–645. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
van der Pas MH, Haglind E, Cuesta MA, Fürst A, Lacy AM, Hop WC and Bonjer HJ: Colorectal cancer laparoscopic or open resection II (COLOR II) study group: laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 14:210–218. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H and Ma Y: Robot-assisted versus conventional laparoscopic surgery for colorectal disease, focusing on rectal cancer: a meta-analysis. Ann Surg Oncol. 19:3727–3736. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lin S, Jiang HG, Chen ZH, Zhou SY, Liu XS and Yu JR: Meta-analysis of robotic and laparoscopic surgery for treatment of rectal cancer. World J Gastroenterol. 17:5214–5220. 2011. View Article : Google Scholar | |
|
Park JS, Choi GS, Lim KH, Jang YS and Jun SH: S052: a comparison of robot-assisted, laparoscopic, and open surgery in the treatment of rectal cancer. Surg Endosc. 25:240–248. 2011. View Article : Google Scholar | |
|
Kim JC, Yang SS, Jang TY, Kwak JY, Yun MJ and Lim SB: Open versus robot-assisted sphincter-saving operations in rectal cancer patients: techniques and comparison of outcomes between groups of 100 matched patients. Int J Med Robot. 8:468–475. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JY, Kim N-K, Lee KY, Hur H, Min BS and Kim JH: A comparative study of voiding and sexual function after total mesorectal excision with autonomic nerve preservation for rectal cancer: laparoscopic versus robotic surgery. Ann Surg Oncol. 19:2485–2493. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
D'Annibale A, Pernazza G, Monsellato I, Pende V, Lucandri G, Mazzocchi P and Alfano G: Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. Surg Endosc. 27:1887–1895. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Luca F, Valvo M, Ghezzi TL, Auccaro M, Cenciarelli S, Trovato C, Sonzogni A and Biffi R: Impact of robotic surgery on sexual and urinary functions after fully robotic nerve-sparing total mesorectal excision for rectal cancer. Ann Surg. 257:672–678. 2013. View Article : Google Scholar | |
|
Collinson FJ, Jayne DG, Pigazzi A, Tsang C, Barrie JM, Edlin R, Garbett C, Guillou P, Holloway I, Howard H, et al: An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. Int J Colorectal Dis. 27:233–241. 2012. View Article : Google Scholar | |
|
Memon S, Heriot AG, Murphy DG, Bressel M and Lynch AC: Robotic versus laparoscopic proctectomy for rectal cancer: a meta-analysis. Ann Surg Oncol. 19:2095–2101. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Trastulli S, Farinella E, Cirocchi R, Cavaliere D, Avenia N, Siannameo F, Gullà N, Noya G and Boselli C: Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. Colorectal Dis. 14:e134–e156. 2012. View Article : Google Scholar | |
|
Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, et al: Scientific committee: multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2). Radiother Oncol. 92:148–163. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann H, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 30:1926–1933. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, et al: ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 23:2479–2516. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T and Martling A: Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III trial. Br J Surg. 100:969–975. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pettersson D, Cedermark B, Holm T, Radu C, Påhlman L, Glimelius B and Martling A: Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 97:580–587. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M and Kryj M: Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 93:1215–1223. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, Mcclure B, Mclachlan SA, et al: Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: trans-tasman radiation oncology group trial 01.04. J Clin Oncol. 30:3827–3833. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel R, Burock S, Wernecke KD, Kretzschmar A, Dietel M, Loy V, Koswig S, budach V and Schlag PM: Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer. 9:502009. View Article : Google Scholar : PubMed/NCBI | |
|
Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et al: Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 13:579–588. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Avallone A, Delrio P, Pecori B, Tatangelo F, Petrillo A, Scott N, Marone P, Aloi L, Sandomenico C, Lastoria S, et al: Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome. Int J Radiat Oncol Biol Phys. 79:670–676. 2011. View Article : Google Scholar | |
|
Gunderson LL, Jessup JM, Sargent DJ, Greene FL and Stewart AK: Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 28:264–271. 2010. View Article : Google Scholar : | |
|
Bombard Y, Bach PB and Offit K: Translating genomics in cancer care. J Natl Compr Canc Netw. 11:1343–1353. 2013.PubMed/NCBI | |
|
Ross JS and Cronin M: Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol. 136:527–539. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: cancer and leukemia group B protocol 89803. J Clin Oncol. 27:1814–1821. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF and B: Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 45:1890–1896. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, et al: Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 30:1755–1762. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G, Salerno S, et al: Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 13:1438–1446. 2002. View Article : Google Scholar : PubMed/NCBI |
